50 states · 6 indications · 300 verified coverage permutations

Does my state Medicaid cover GLP-1s for weight loss, CV, OSA, MASH, pediatric, or T2D?

Pick your state and the indication you're asking about. The pre-screener returns the coverage status, the verbatim primary-source quote, the prior-authorization mechanics, the appeals pathway, the pharmacy-benefit manager (PBM), the managed-care structure, and a direct link to the full state research article. Every state row carries a verified-date badge showing when the WLR editorial team last confirmed the data against the state Medicaid agency's primary source.

How to read the verified-date badge: any badge older than 90 days warrants a fresh confirmation with your state Medicaid program — Preferred Drug List (PDL) updates, State Plan Amendment (SPA) carve-ins/carve-outs, and PBM contract changes can flip a coverage status mid-year. Use the linked state article for the deeper PA-form, fibrosis-stage, BMI-threshold, and AHI-threshold detail.

YMYL disclaimer — data lookup only, not coverage prediction

This tool surfaces verified state-Medicaid coverage data; it is NOT medical, legal, or benefits advice. Individual coverage decisions depend on your specific eligibility category, managed-care plan assignment, comorbidities, and prior treatment history. Confirm directly with your state Medicaid program or your managed-care plan's member services line before assuming coverage. Prior-authorization criteria, BMI thresholds, and fibrosis-stage requirements can change without notice between editorial reviews.

50-state coverage overview (chronic weight management)

Derived directly from src/data/state-medicaid-coverage.json — the counter cards below recompute on every build from the underlying data file. Use these to size the national picture before drilling into your specific state.

13

states cover obesity indication

Wegovy, Zepbound, Saxenda, or Contrave on Medicaid PDL for chronic weight management with PA criteria

3

states facing sunset proposals

Coverage announced to end on a specific future date (MassHealth, Rhode Island, Utah)

4

states dropped coverage 2025–2026

California Medi-Cal Rx, New Hampshire, Pennsylvania, South Carolina — denials effective on stated cutoff dates

33

categorical-exclusion states

No chronic-weight-management coverage on Medicaid PDL; CV / OSA / MASH carve-outs may still apply

Look up your state and indication

Select your state and the indication you're asking about. The tool returns the verified coverage status, verbatim primary-source quote, PA form / fax / phone, appeals pathway, PBM, and a link to the full state research brief.

Indication

Select your state above to see verified GLP-1 coverage data, PA mechanics, and the verbatim primary-source quote.

How to read the coverage status

  • Covered with PA — On the state Medicaid Preferred Drug List (PDL) for this indication. The prescriber must submit a prior-authorization request documenting BMI, comorbidities, and (for OSA / MASH / pediatric) the indication-specific clinical criteria.
  • Covered (sunset pending) — Currently covered, but the state Medicaid agency has announced an end date. PAs filed before the sunset date may still pay through the announced cutoff; new starts may be denied.
  • Carve-out only (PA required) — Not covered for chronic weight management as a primary indication, but covered for a specific carve-out (e.g., cardiovascular risk reduction with established CVD, or OSA with apnea-hypopnea index above the state threshold). PA criteria are narrower and indication-specific.
  • Not covered — Excluded from the state Medicaid PDL for this indication. The patient pays cash, uses a manufacturer self-pay program, or pursues a telehealth cash-pay route. Some states with categorical chronic-weight-management exclusions still cover CV / OSA / MASH carve-outs — check the other tabs.
  • Dropped — The state Medicaid agency previously covered this indication and has since terminated coverage. All prior PAs expire on the stated cutoff date.
  • Unverified — The WLR editorial team has not yet confirmed coverage for this specific indication against the state Medicaid agency's primary source. Confirm with your prescriber or the state Medicaid PBM before assuming coverage.

How this data is verified

The 50-state coverage dataset is backfilled from the WLR state-Medicaid research series, where every state brief anchors on the state Medicaid agency's published Preferred Drug List (PDL), State Plan Amendments (SPAs), PA criteria documents, and managed-care PBM formularies. For broader context the dataset also references the Kaiser Family Foundation January 16, 2026 issue brief (“Medicaid Coverage of and Spending on GLP-1s”) and the Stateline April 30, 2025 reporting on state sunset proposals. Every state row carries a verified-date badge in lastVerified ISO format; click through to the linked state article for the deeper editorial review.

What this tool is NOT

This tool is a data lookup, not a coverage predictor. It will not tell you whether your specific prior-authorization request will be approved — that depends on your individual eligibility category, managed-care plan assignment, BMI, comorbidities, fibrosis stage (for MASH), apnea-hypopnea index (for OSA), prior weight-management history, and the clinical judgment of the state Medicaid medical director or PBM reviewer. Always confirm coverage directly with your state Medicaid program before assuming a result. Coverage policies can change mid-year via PDL updates, SPA filings, or PBM contract renegotiations.

Related tools and articles

Important disclaimer

This tool is for informational and educational use only and does not constitute medical, legal, or benefits advice. State Medicaid coverage information is sourced from publicly published PDLs, SPAs, and PA criteria; it is not authoritative and may not reflect last-minute policy changes. Weight Loss Rankings is not affiliated with any state Medicaid agency. Always verify coverage with your state Medicaid program, your managed-care plan's member services line, or your prescriber before making any treatment decisions. For appeals timelines and procedures, consult the state regulation cited in your specific state row.

References

  1. 1.Kaiser Family Foundation (Williams E, Hinton E, Rudowitz R). Medicaid Coverage of and Spending on GLP-1s — Issue Brief. KFF. 2026. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
  2. 2.Stateline (Vestal C). More states are dropping Medicaid coverage of pricey weight-loss drugs. Stateline. 2025. https://stateline.org/2025/04/30/more-states-are-dropping-medicaid-coverage-of-pricey-weight-loss-drugs/
  3. 3.healthinsurance.org. Medicaid eligibility and enrollment — state expansion tracker. healthinsurance.org. 2026. https://www.healthinsurance.org/medicaid/
  4. 4.Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program — covered outpatient drugs and State Plan Amendment (SPA) tracker. Medicaid.gov. 2026. https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html
  5. 5.Weight Loss Rankings Editorial Team. 50-state Medicaid GLP-1 coverage and prior-authorization pathway series (50 state research briefs). Weight Loss Rankings. 2026. https://www.weightlossrankings.org/insurance/state-medicaid